Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.

Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE, Pazdur R.

Clin Cancer Res. 2018 Nov 9. doi: 10.1158/1078-0432.CCR-18-2743. [Epub ahead of print]

PMID:
30413526
2.

Dose Finding in Late-Phase Drug Development.

Nie L, Lee KY, Verdun N, De Claro RA, Sridhara R.

Ther Innov Regul Sci. 2017 Nov;51(6):738-743. doi: 10.1177/2168479017709297. Epub 2017 May 30.

PMID:
30227101
3.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review.

4.

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.

Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R.

Oncologist. 2017 May;22(5):585-591. doi: 10.1634/theoncologist.2017-0004. Epub 2017 Apr 24.

5.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.

de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Aug 15;21(16):3586-90. doi: 10.1158/1078-0432.CCR-14-2225.

6.

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.

Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, Gudi R, Saber H, Shord S, Bullock J, Marathe D, Mehrotra N, Hsieh LS, Ghosh D, Brown J, Kane RC, Justice R, Kaminskas E, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Apr 1;21(7):1525-9. doi: 10.1158/1078-0432.CCR-14-2522. Epub 2015 Feb 2.

7.

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R.

Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.

8.

Hematopoietic Fas deficiency does not affect experimental atherosclerotic lesion formation despite inducing a proatherogenic state.

de Claro RA, Zhu X, Tang J, Morgan-Stevenson V, Schwartz BR, Iwata A, Liles WC, Raines EW, Harlan JM.

Am J Pathol. 2011 Jun;178(6):2931-7. doi: 10.1016/j.ajpath.2011.02.011. Epub 2011 May 6.

9.

Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsis.

Iwata A, de Claro RA, Morgan-Stevenson VL, Tupper JC, Schwartz BR, Liu L, Zhu X, Jordan KC, Winn RK, Harlan JM.

PLoS One. 2011 Feb 24;6(2):e14729. doi: 10.1371/journal.pone.0014729.

10.

Differences in F36VMpl-based in vivo selection among large animal models.

Richard RE, De Claro RA, Yan J, Chien S, Von Recum H, Morris J, Kiem HP, Dalgarno DC, Heimfeld S, Clackson T, Andrews R, Blau CA.

Mol Ther. 2004 Oct;10(4):730-40.

Supplemental Content

Loading ...
Support Center